Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms

被引:45
作者
Zhang, Lixin [1 ]
Vlad, Anda [1 ,2 ]
Milcarek, Christine [1 ]
Finn, Olivera J. [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Med, Dept Obstet & Gynecol, Pittsburgh, PA 15261 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
MUC1; Alternative splicing; Isoforms; Tumor; DENDRITIC CELLS; ANTIGEN MUC1; T-CELLS; CANCER; EXPRESSION; TRANSCRIPTOME; ANTIBODIES; MUTATIONS; EPISIALIN; SELECTION;
D O I
10.1007/s00262-012-1325-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MUC1 is a transmembrane mucin with important functions in normal and transformed cells, carried out by the extracellular domain or the cytoplasmic tail. A characteristic feature of the MUC1 extracellular domain is the variable number of tandem repeats (VNTR) region. Alternative splicing may regulate MUC1 expression and possibly function. We developed an RT-PCR method for efficient isolation of MUC1 mRNA isoforms that allowed us to evaluate the extent of alternative splicing of MUC1 and elucidate some of the rules that govern this process. We cloned and analyzed 21, 24, and 36 isoforms from human tumor cell lines HeLa, MCF7, and Jurkat, respectively, and 16 from normal activated human T cells. Among the 78 MUC1 isoforms we isolated, 76 are new and different cells showed varied MUC1 expression patterns. The VNTR region of exon 2 was recognized as an intron with a fixed 5' splice site but variable 3' splice sites. We also report that the 3506 A/G SNP in exon 2 can regulate 3' splice sites selection in intron 1 and produce different MUC1 short isoform proteins. Furthermore, the SNP A to G mutation was also observed in vivo, during de novo tumor formation in MUC1(+/-)Kras(G12D/+)Pten(loxP/loxP) mice. No specific functions have been associated with previously reported short isoforms. We now report that one new G SNP-associated isoform MUC1/Y-LSP, but not the A SNP-associated isoform MUC1/Y, inhibits tumor growth in immunocompetent but not immunocompromised mice.
引用
收藏
页码:423 / 435
页数:13
相关论文
共 64 条
[1]  
Agrawal B, 1998, CANCER RES, V58, P4079
[2]   SPECIFIC, MAJOR HISTOCOMPATIBILITY COMPLEX - UNRESTRICTED RECOGNITION OF TUMOR-ASSOCIATED MUCINS BY HUMAN CYTO-TOXIC T-CELLS [J].
BARND, DL ;
LAN, MS ;
METZGAR, RS ;
FINN, OJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (18) :7159-7163
[3]  
Baruch A, 1997, INT J CANCER, V71, P741
[4]   Alternative splicing: New insights from global analyses [J].
Blencowe, Benjamin J. .
CELL, 2006, 126 (01) :37-47
[5]   Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer [J].
Budiu, Raluca A. ;
Mantia-Smaldone, Gina ;
Elishaev, Esther ;
Chu, Tianjiao ;
Thaller, Julia ;
McCabe, Kathryn ;
Lenzner, Diana ;
Edwards, Robert P. ;
Vlad, Anda M. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (07) :975-984
[6]   A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+regulatory T cells [J].
Budiu, Raluca A. ;
Diaconu, Iulia ;
Chrissluis, Rachel ;
Dricu, Anica ;
Edwards, Robert P. ;
Vlad, Anda M. .
DISEASE MODELS & MECHANISMS, 2009, 2 (11-12) :593-603
[7]   Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity [J].
Carlos, CA ;
Dong, HF ;
Howard, OMZ ;
Oppenheim, JJ ;
Hanisch, FG ;
Finn, OJ .
JOURNAL OF IMMUNOLOGY, 2005, 175 (03) :1628-1635
[8]   The Cytoplasmic Tail of MUC1: A Very Busy Place [J].
Carson, Daniel D. .
SCIENCE SIGNALING, 2008, 1 (27) :pe35
[9]   Listening to silence and understanding nonsense: Exonic mutations that affect splicing [J].
Cartegni, L ;
Chew, SL ;
Krainer, AR .
NATURE REVIEWS GENETICS, 2002, 3 (04) :285-298
[10]   Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration [J].
Correa, I ;
Plunkett, T ;
Vlad, A ;
Mungul, A ;
Candelora-Kettel, J ;
Burchell, JM ;
Taylor-Papadimitriou, J ;
Finn, OJ .
IMMUNOLOGY, 2003, 108 (01) :32-41